{
  "id": 5171669,
  "title": "Lantheus Holdings sells $245,609 in Perspective Therapeutics stock",
  "url": "https://urgent.news/2026/09/02/lantheus-holdings-sells-245-609-in-perspective-therapeutics-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-02T21:00:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/lantheus-holdings-sells-245609-in-perspective-therapeutics-stock-93CH-4886778"
  },
  "original_language": "en",
  "account": "Lantheus Holdings, Inc., a significant stakeholder and director of Perspective Therapeutics, Inc., divested shares of the company's common stock worth $245,609 on August 31, 2026. The sale comprised 78,145 shares, executed through several transactions at prices spanning from $3.095 to $3.165 per share, yielding a weighted average sale price of $3.143. The transaction unfolded at a time when CATX stock was trading at $3.10, marking a 42% decline over the preceding six months, although it had still registered a 13% gain year-to-date.\n\nAccording to InvestingPro analysis, which examines 11 additional critical indicators for CATX, market analysts continue to express a robust buy consensus, with price targets ranging from $5 to $18, signaling substantial upside potential despite the insider sale. Consequently, Lantheus Holdings, Inc. now holds 11,599,194 shares of Perspective Therapeutics, directly through Lantheus Alpha Therapy, LLC, a wholly-owned subsidiary, potentially qualifying as indirect beneficial ownership. The disclosed share quantity has been corrected for a 1-for-10 reverse stock split carried out by Perspective Therapeutics on June 14, 2024.\n\nRecent remarks from various analysts on Perspective Therapeutics have added to the company's evolving narrative. BMO Capital initiated coverage on the firm with an Outperform rating and set a price target of $11. Piper Sandler revised its price target for Perspective Therapeutics to $14 from a prior $16, retaining an Overweight rating, a move tied to the firm's Q2 2026 earnings report, which reaffirmed anticipations for key site activation expected by the end of 2026. BTIG likewise reaffirmed its Buy rating, adjusting the price target to $14 from a prior $16, emphasizing the company's manufacturing competencies as a competitive advantage and positioning it as a top pick for the latter half of 2026. These recent analyst updates illustrate the diverse views on Perspective Therapeutics' future trajectory.",
  "summary": null,
  "key_points": [
    "Lantheus Holdings sold 78,145 shares of Perspective Therapeutics for $245,609 on August 31, 2026.",
    "The sale occurred at a time when CATX stock declined 42% over six months.",
    "Analysts maintain a buy consensus with price targets ranging from $5 to $18."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}